Provided by Tiger Trade Technology Pte. Ltd.

JPMORGAN HEALTHCARE LEADERS ETF

59.56
+0.08390.14%
Post-market: 59.47-0.0839-0.14%16:10 EDT
Volume:46
Turnover:3K
Market Cap:8.93M
PE:- -
High:59.56
Open:59.47
Low:59.56
Close:59.47
52wk High:64.69
52wk Low:53.59
Shares:150.00K
Float Shares:150.00K
Volume Ratio:0.55
T/O Rate:0.03%
Dividend:0.51
Dividend Rate:0.86%
ROE:--
ROA:--
PB:--
PE(LYR):- -

Loading ...

After GLP-1, the Next Card: Why Eli Lilly and Novo Nordisk Are Both Betting on Amylin

Deep News
·
2 hours ago

Eli Lilly & Co (LLY) Gets a Buy from RBC Capital

TIPRANKS
·
7 hours ago

Perrigo Co. PLC Stock Outperforms Competitors on Strong Trading Day

Dow Jones
·
11 hours ago

AbbVie Joins US Government Pilot to Test Drug Discount Rebates

Reuters
·
12 hours ago

AbbVie Inc. Stock Outperforms Competitors on Strong Trading Day

Dow Jones
·
12 hours ago

Abbvie-from Jan 1, 2027, Covered Entities to Submit Claims to GET 340B Pricing Through Beacon on 340B-Eligible Dispenses of Imbruvica, Linzess,Vraylar

THOMSON REUTERS
·
13 hours ago

Abbvie - Approved to Participate in Federal 340B Rebate Model Pilot Program

THOMSON REUTERS
·
13 hours ago

Former Eli Lilly Exec Sells Wyoming Estate for Close to $39.5 Million

Dow Jones
·
13 hours ago

Why Medtronic's $4 Billion MiniMed Exchange Offer is Losing Its Allure

Dow Jones
·
14 hours ago

Eli Lilly announces FDA approves additional indication for Jaypirca

TIPRANKS
·
14 hours ago

Lilly Says FDA Approves Expanded First-Line Cll/sll Use for Jaypirca

Reuters
·
14 hours ago

Lilly's Jaypirca (Pirtobrutinib), the First-and-Only Approved Non-Covalent Btk Inhibitor, Receives Expanded Indication from U.S. FDA for Certain Patients with Previously Untreated Cll/Sll

THOMSON REUTERS
·
14 hours ago

Legend Biotech Faces Pressure From Rivals Ahead of Key FDA Decision, UBS Says

MT Newswires Live
·
16 hours ago

AbbVie’s Venetoclax AML Study in Greece: What the Latest Update Means for Investors

TIPRANKS
·
16 hours ago

Correction: Top Midday Decliners

MT Newswires Live
·
Yesterday

Abogen announces licensing, option agreement with Novartis

TIPRANKS
·
Yesterday

Johnson & Johnson announces two-year data from Phase 3 ICONIC-TOTAL study

TIPRANKS
·
Yesterday

Johnson & Johnson Says Icotyde Sustains Psoriasis Skin Clearance Through 2 Years in Phase 3 Iconic-TOTAL Study

Reuters
·
Yesterday

J&J - Icotyde-Treated Patients Show 70% Clear or Almost Clear Skin at Week 112

THOMSON REUTERS
·
Yesterday

Johnson & Johnson Announces New Icotyde® (Icotrokinra) Data in Difficult-to-Treat Plaque Psoriasis with Proven Durability Through 2-Years, Affirming Its Use as a Powerful First Line Systemic Therapy~

THOMSON REUTERS
·
Yesterday